Maximum quantity allowed is 999
CAS RN: 157212-55-0 | Product Number: B5118
Bosentan Monohydrate
Purity: >98.0%(HPLC)
- 4-(tert-Butyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide Monohydrate
- 4-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide Monohydrate
| Size | Unit Price | Saitama (Kawaguchi) | Hyogo (Amagasaki) | Stock in other WH |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
¥7,900
|
13 | 2 | Contact Us | |
| 100MG |
¥24,000
|
Contact Us | Contact Us | Contact Us |
* The displayed price is the unit price and does not include consumption tax. The unit prices displayed are the latest and are subject to change without notice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | B5118 |
Purity / Analysis Method
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__2__9N__5O__6S·H__2O = 569.64 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container
|
25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 157212-55-0 |
Related CAS RN
|
147536-97-8 |
| Reaxys Registry Number | 9031515 |
| PubChem Substance ID | 354334055 |
| Merck Index (14) | 1353 |
| MDL Number | MFCD09751188 |
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.60 to 12.90 % |
| Water | 2.5 to 4.0 % |
| NMR | confirm to structure |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Ethanol |
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
References
- Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
- Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan)
- Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist
- Clinical pharmacology of bosentan, a dual endothelin receptor antagonist (a review)
- Role of endothelin in fibrosis and anti-fibrotic potential of bosentan (a review)
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.